Medistep Healthcare IPO Opens August 8: Price, Dates & Investor Guide

The Indian pharmaceutical sector gains a fresh contender as Medistep Healthcare Limited prepares for its highly anticipated ₹16.09 crore Initial Public Offering (IPO). Scheduled to open on August 8, 2025, and close on August 12, 2025, this NSE SME listing marks a pivotal moment for the fast-growing manufacturer of sanitary pads, energy powders, and diverse pharmaceutical products. Shares are expected to list on August 18, 2025, offering retail and institutional investors a stake in a company demonstrating robust financial momentum.

Medistep Healthcare IPO: Key Dates and Structure

Investors should note these critical details:

• Price Band: Fixed at ₹43 per equity share (face value ₹10)
• Total Issue Size: 374,400 equity shares
• Lot Size: Minimum investment of 3,000 shares
• Lead Manager: Fast Track Finsec Private Limited
• Registrar: Cameo Corporate Services Limited

Allotment is strategically segmented:

• Retail Investors: Reserved 177,900 shares
• Non-Institutional Investors (NIIs): Allocated 177,600 shares
• Market Makers: Set aside 18,900 shares

This structure aims to balance broad public participation with strategic market support upon listing.

How Will Medistep Healthcare Utilize IPO Funds?

Proceeds from the IPO are earmarked for strategic expansion and operational efficiency:

• Expanding Production Capacity: Acquiring new machinery to scale output of sanitary pads, energy powders, and pharmacuticals.
• Working Capital Reinforcement: Ensuring seamless supply chain operations for its diverse portfolio, including nutraceuticals and intimate care products.
• Market Penetration: Funding deeper entry into domestic and international markets.
• General Corporate Purposes: Supporting infrastructure and R&D initiatives.

Giridhari Lal Prajapati, Managing Director of Medistep Healthcare, emphasized the vision: “The IPO empowers our expansion plans, strengthens our pan-India and export footprint, and enhances our diverse portfolio. Our focus on sustainable, hygiene-focused products positions us to capitalize on rising global health awareness.

Financial Performance and Growth Trajectory

Medistep Healthcare showcases impressive financial health, validating investor confidence:

• Revenue Surge: FY25 revenue soared to ₹49.65 crore, a significant jump from ₹39.07 crore in FY24.
• Profitability Growth: EBITDA climbed to ₹5.60 crore in FY25 (up from ₹4.54 crore in FY24), while PAT (Profit After Tax) reached ₹4.14 crore (versus ₹3.33 crore in FY24).
• Post-IPO Valuation: Expected market capitalization stands at ₹61.10 crore.

Founded in 2023, the company rapidly scaled by acquiring M/s MG Pharma (established 2018) in 2024. This integration bolstered its manufacturing capabilities across multiple product categories, fueling its revenue acceleration and operational synergy.

Medistep Healthcare’s IPO arrives amid surging demand for affordable, quality healthcare products in India and globally. With strong financials, a diversified product line, and clear growth objectives, it presents a compelling opportunity. However, potential investors must scrutinize market risks and consult financial advisors before committing capital. Act now to evaluate this promising entry into the booming healthcare manufacturing sector.

---

Must Know

What is Medistep Healthcare’s IPO price?
The IPO price is fixed at ₹43 per equity share. This applies uniformly to all investor categories (retail, NII, market makers) for the ₹16.09 crore offering.

When can I apply for the Medistep Healthcare IPO?
The subscription window opens on August 8, 2025, and closes on August 12, 2025. Allotments will be finalized before the expected NSE SME listing date of August 18, 2025.

What products does Medistep Healthcare manufacture?
Medistep produces sanitary pads, energy powders, pharmaceuticals, nutraceuticals, intimate care items, and surgical products. Its integrated portfolio targets mass-market and export demand.

How has Medistep Healthcare performed financially?
The company reported robust growth: FY25 revenue hit ₹49.65 crore (up 27% YoY), while PAT reached ₹4.14 crore (up 24.5%). This underscores efficient scaling and market acceptance.

Where will Medistep use the IPO funds?
Primary allocations include working capital, machinery procurement, and factory expansion. A portion will also fund corporate initiatives and market outreach.

What is Medistep’s post-IPO market cap?
Upon listing, Medistep Healthcare’s market capitalization is projected to be ₹61.10 crore, reflecting its current financial scale and growth ambitions.